# SuperFolder COVID-19 mRNA vaccine
An mRNA for the SARS-CoV-2 Spike glycoprotein antigen (the prefusion stabilized variant, S-2P), stabilized against hydrolysis, for testing in COVID-19 mRNA vaccines. 

This **open source mRNA vaccine** is being made available in the public domain to aid any efforts seeking to deliver COVID-19 mRNA vaccines in prefilled syringes without freezing. 

The codons of this *Superfolder S-2P mRNA* have been redesigned to produce a highly stable mRNA structure predicted to have ~3x longer lifetime in (non-frozen) aqueous storage, based on computational design rules, algorithms, and a large corpus of experimental data developed through 2020 in the **OpenVaccine** project, based at Stanford University.

For avoidance of doubt, an [Open Covid License](LICENSE) is enclosed with this repository that grants license to any party for use of this sequence and enclosed data in research or product development that could accelerate the end of the COVID-19 pandemic. 

## The RNA sequence
```
> OpenVaccine Superfolder-v2 S-2P mRNA (Eterna 10645690, AB_Wayment_Mod)
AUGUUUGUUUUUUUAGUCCUCUUGCCGCUGGUUUCGAGUCAGUGCGUCAACCUUACGACGCGGACGCAGCUGCCGCCGGCCUACACGAACUCCUUCACGCGGGGGGUGUACUACCCCGACAAGGUGUUCCGCUCGUCUGUUCUGCACAGCACGCAGGACCUCUUCCUCCCGUUCUUCUCGAACGUGACGUGGUUCCACGCCAUUCACGUGUCGGGGACGAACGGGACGAAGAGGUUCGACAACCCUGUUCUGCCGUUCAACGACGGGGUGUACUUCGCUUCGACGGAGAAGUCCAACAUUAUUCGCGGGUGGAUAUUCGGGACCACUCUCGAUUCGAAGACUCAGUCCUUGCUGAUAGUGAACAACGCGACGAACGUGGUCAUUAAGGUCUGCGAGUUCCAGUUCUGUAAUGACCCGUUCCUCGGUGUUUACUAUCACAAGAACAACAAGUCUUGGAUGGAGAGUGAGUUCCGGGUGUACUCGUCCGCGAAUAAUUGUACGUUCGAGUAUGUGAGCCAGCCGUUCCUGAUGGAUCUUGAGGGCAAGCAGGGCAAUUUCAAGAAUUUGCGCGAGUUUGUCUUCAAGAACAUCGACGGCUACUUCAAGAUAUACUCGAAGCACACGCCGAUCAACCUCGUCCGUGAUCUCCCGCAGGGGUUCAGCGCGCUGGAGCCGCUGGUGGACCUGCCGAUCGGGAUCAACAUCACGCGGUUCCAGACGCUGCUGGCCCUGCACCGGAGUUACCUGACGCCGGGUGACUCCAGUUCCGGGUGGACUGCGGGUGCCGCCGCGUACUACGUGGGGUACCUGCAGCCGCGGACGUUCUUGUUGAAGUACAACGAGAACGGGACGAUCACGGACGCGGUUGAUUGCGCGUUGGACCCUCUGUCGGAGACGAAGUGCACCCUGAAGUCGUUCACGGUGGAGAAGGGGAUCUAUCAGACCUCCAACUUCCGGGUCCAGCCGACUGAGAGUAUCGUUCGGUUCCCGAACAUCACGAACCUGUGUCCGUUCGGGGAGGUCUUCAACGCGACGCGGUUCGCCUCCGUGUACGCUUGGAACCGGAAGAGGAUCUCGAAUUGUGUGGCGGACUACAGUGUGCUGUACAAUUCGGCGUCCUUUUCCACUUUCAAGUGUUACGGGGUGUCGCCCACGAAGUUGAACGACCUCUGCUUCACCAACGUGUACGCGGAUUCCUUCGUCAUCCGUGGGGACGAGGUCAGGCAGAUCGCGCCCGGGCAGACUGGGAAGAUAGCGGACUACAAUUAUAAGUUGCCCGACGACUUUACUGGCUGCGUUAUUGCUUGGAACAGCAAUAACCUGGACAGUAAGGUCGGGGGCAACUAUAAUUACCUGUACCGGCUGUUCCGGAAGAGCAAUCUGAAGCCCUUCGAGCGCGACAUUAGCACGGAGAUCUACCAGGCGGGUAGCACUCCGUGCAAUGGCGUGGAGGGCUUCAAUUGCUACUUUCCGCUGCAGUCGUACGGGUUUCAGCCCACCAACGGGGUGGGGUACCAGCCCUACCGCGUGGUGGUGCUGAGCUUCGAGCUCCUUCACGCGCCCGCGACGGUCUGUGGGCCCAAGAAGUCGACGAACUUAGUGAAGAACAAGUGCGUCAACUUCAACUUCAAUGGGCUCACGGGCACGGGGGUGCUGACGGAGUCGAACAAGAAGUUCCUGCCUUUCCAGCAGUUCGGGCGCGAUAUUGCCGACACCACGGAUGCCGUGAGGGAUCCGCAGACGCUUGAGAUUCUGGACAUCACGCCCUGCAGCUUCGGGGGCGUCAGUGUGAUCACGCCUGGUACGAACACGAGCAACCAGGUUGCCGUGUUGUACCAGGACGUGAAUUGCACUGAGGUCCCCGUAGCGAUCCACGCGGAUCAGCUGACCCCGACGUGGAGGGUGUACUCGACGGGGAGUAAUGUAUUUCAGACGCGGGCUGGUUGUCUGAUUGGUGCGGAGCACGUAAACAACUCCUAUGAGUGUGACAUACCCAUAGGAGCUGGCAUAUGUGCUUCGUACCAGACUCAGACAAACAGCCCGCGUCGAGCCCGGAGCGUUGCGUCGCAGAGCAUAAUCGCGUACACGAUGUCCCUCGGGGCGGAGAAUUCGGUGGCAUAUAGUAACAACAGUAUUGCCAUACCGACGAACUUCACGAUCUCCGUGACCACCGAGAUACUGCCGGUGAGCAUGACUAAGACGAGUGUAGACUGUACGAUGUAUAUCUGCGGCGACAGUACUGAGUGCAGUAACCUGUUGCUGCAGUAUGGGUCGUUCUGCACUCAGCUUAAUCGUGCUCUUACCGGGAUCGCCGUAGAGCAGGAUAAGAACACGCAGGAGGUCUUUGCGCAGGUGAAGCAGAUCUACAAGACUCCGCCUAUCAAGGACUUCGGCGGGUUCAACUUCAGCCAGAUUCUGCCAGACCCAUCUAAGCCGAGCAAGAGGUCCUUUAUUGAGGACCUCUUGUUCAACAAGGUGACUCUGGCAGAUGCUGGCUUUAUCAAGCAGUACGGCGAUUGUCUCGGGGACAUCGCUGCGCGCGAUUUGAUCUGUGCGCAAAAGUUCAACGGGCUCACUGUGCUACCACCUCUCCUGACGGACGAGAUGAUAGCACAGUAUACCAGCGCGCUGUUGGCUGGUACGAUCACUUCUGGUUGGACGUUCGGGGCGGGUGCGGCACUCCAGAUCCCGUUCGCCAUGCAGAUGGCGUACCGGUUCAACGGGAUCGGAGUGACGCAGAACGUCCUGUACGAAAACCAGAAGUUGAUCGCCAACCAGUUCAACAGCGCGAUUGGUAAGAUACAGGACUCCCUGUCGAGUACGGCCUCCGCGUUGGGGAAGCUGCAGGACGUGGUGAACCAGAAUGCUCAGGCGUUGAACACGUUGGUGAAGCAGCUGUCGUCCAACUUCGGGGCGAUAAGUUCGGUGCUGAACGAUAUUCUCAGUCGGCUGGACCCGCCGGAGGCGGAGGUCCAGAUAGAUCGGCUCAUCACUGGUCGCCUCCAGAGUUUGCAGACGUACGUGACUCAGCAGCUCAUCCGGGCUGCUGAGAUACGUGCGUCUGCGAACCUGGCGGCGACCAAGAUGAGCGAGUGCGUGCUGGGGCAGAGCAAGCGGGUGGACUUCUGCGGGAAGGGGUAUCACCUGAUGUCCUUCCCGCAGAGCGCGCCUCACGGGGUGGUCUUCCUGCACGUGACGUAUGUGCCGGCGCAGGAGAAGAACUUCACCACGGCGCCGGCGAUAUGUCACGACGGGAAGGCGCACUUCCCGCGUGAGGGGGUUUUUGUUUCGAACGGGACGCACUGGUUCGUCACGCAGCGCAACUUCUAUGAGCCGCAGAUAAUUACCACUGACAACACGUUUGUCAGUGGUAAUUGUGAUGUGGUCAUAGGGAUCGUGAACAACACGGUCUACGAUCCCCUGCAGCCCGAGCUGGAUAGUUUCAAGGAGGAGCUUGAUAAGUACUUCAAGAAUCAUACUUCCCCGGACGUGGAUCUUGGCGACAUUAGCGGGAUCAACGCUAGUGUCGUCAACAUCCAGAAGGAGAUCGACAGGCUCAAUGAGGUUGCGAAGAACCUCAACGAGAGCCUGAUCGAUCUCCAGGAGUUGGGGAAGUAUGAGCAGUACAUCAAGUGGCCUUGGUACAUCUGGCUCGGGUUCAUCGCGGGGCUGAUCGCGAUCGUGAUGGUCACGAUCAUGUUGUGCUGCAUGACGAGCUGCUGCUCCUGUUUGAAGGGCUGCUGCAGCUGCGGUUCGUGUUGUAAGUUUGACGAGGAUGACUCGGAGCCGGUGCUCAAGGGGGUGAAGCUGCACUACACGUGA
```
The RNA above also includes a stop codon. 
*Feel free to copy/paste this sequence and use directly in your research or product development.* 

The above RNA has also been modified to code for the spike protein of strain B.1.351.

```
> OpenVaccine Superfolder-v2 S-2P B.1.351 mRNA 
AUGUUUGUUUUUUUAGUCCUCUUGCCGCUGGUUUCGAGUCAGUGCGUCAACUUCACGACGCGGACGCAGCUGCCGCCGGCCUACACGAACUCCUUCACGCGGGGGGUGUACUACCCCGACAAGGUGUUCCGCUCGUCUGUUCUGCACAGCACGCAGGACCUCUUCCUCCCGUUCUUCUCGAACGUGACGUGGUUCCACGCCAUUCACGUGUCGGGGACGAACGGGACGAAGAGGUUCGCGAACCCUGUUCUGCCGUUCAACGACGGGGUGUACUUCGCUUCGACGGAGAAGUCCAACAUUAUUCGCGGGUGGAUAUUCGGGACCACUCUCGAUUCGAAGACUCAGUCCUUGCUGAUAGUGAACAACGCGACGAACGUGGUCAUUAAGGUCUGCGAGUUCCAGUUCUGUAAUGACCCGUUCCUCGGUGUUUACUAUCACAAGAACAACAAGUCUUGGAUGGAGAGUGAGUUCCGGGUGUACUCGUCCGCGAAUAAUUGUACGUUCGAGUAUGUGAGCCAGCCGUUCCUGAUGGAUCUUGAGGGCAAGCAGGGCAAUUUCAAGAAUUUGCGCGAGUUUGUCUUCAAGAACAUCGACGGCUACUUCAAGAUAUACUCGAAGCACACGCCGAUCAACCUCGUCCGUGGGCUCCCGCAGGGGUUCAGCGCGCUGGAGCCGCUGGUGGACCUGCCGAUCGGGAUCAACAUCACGCGGUUCCAGACGCUGCACAUCAGUUACCUGACGCCGGGUGACUCCAGUUCCGGGUGGACUGCGGGUGCCGCCGCGUACUACGUGGGGUACCUGCAGCCGCGGACGUUCUUGUUGAAGUACAACGAGAACGGGACGAUCACGGACGCGGUUGAUUGCGCGUUGGACCCUCUGUCGGAGACGAAGUGCACCCUGAAGUCGUUCACGGUGGAGAAGGGGAUCUAUCAGACCUCCAACUUCCGGGUCCAGCCGACUGAGAGUAUCGUUCGGUUCCCGAACAUCACGAACCUGUGUCCGUUCGGGGAGGUCUUCAACGCGACGCGGUUCGCCUCCGUGUACGCUUGGAACCGGAAGAGGAUCUCGAAUUGUGUGGCGGACUACAGUGUGCUGUACAAUUCGGCGUCCUUUUCCACUUUCAAGUGUUACGGGGUGUCGCCCACGAAGUUGAACGACCUCUGCUUCACCAACGUGUACGCGGAUUCCUUCGUCAUCCGUGGGGACGAGGUCAGGCAGAUCGCGCCCGGGCAGACUGGGAACAUAGCGGACUACAAUUAUAAGUUGCCCGACGACUUUACUGGCUGCGUUAUUGCUUGGAACAGCAAUAACCUGGACAGUAAGGUCGGGGGCAACUAUAAUUACCUGUACCGGCUGUUCCGGAAGAGCAAUCUGAAGCCCUUCGAGCGCGACAUUAGCACGGAGAUCUACCAGGCGGGUAGCACUCCGUGCAAUGGCGUGAAGGGCUUCAAUUGCUACUUUCCGCUGCAGUCGUACGGGUUUCAGCCCACCUACGGGGUGGGGUACCAGCCCUACCGCGUGGUGGUGCUGAGCUUCGAGCUCCUUCACGCGCCCGCGACGGUCUGUGGGCCCAAGAAGUCGACGAACUUAGUGAAGAACAAGUGCGUCAACUUCAACUUCAAUGGGCUCACGGGCACGGGGGUGCUGACGGAGUCGAACAAGAAGUUCCUGCCUUUCCAGCAGUUCGGGCGCGAUAUUGCCGACACCACGGAUGCCGUGAGGGAUCCGCAGACGCUUGAGAUUCUGGACAUCACGCCCUGCAGCUUCGGGGGCGUCAGUGUGAUCACGCCUGGUACGAACACGAGCAACCAGGUUGCCGUGUUGUACCAGGGCGUGAAUUGCACUGAGGUCCCCGUAGCGAUCCACGCGGAUCAGCUGACCCCGACGUGGAGGGUGUACUCGACGGGGAGUAAUGUAUUUCAGACGCGGGCUGGUUGUCUGAUUGGUGCGGAGCACGUAAACAACUCCUAUGAGUGUGACAUACCCAUAGGAGCUGGCAUAUGUGCUUCGUACCAGACUCAGACAAACAGCCCGCGUCGAGCCCGGAGCGUUGCGUCGCAGAGCAUAAUCGCGUACACGAUGUCCCUCGGGGUCGAGAAUUCGGUGGCAUAUAGUAACAACAGUAUUGCCAUACCGACGAACUUCACGAUCUCCGUGACCACCGAGAUACUGCCGGUGAGCAUGACUAAGACGAGUGUAGACUGUACGAUGUAUAUCUGCGGCGACAGUACUGAGUGCAGUAACCUGUUGCUGCAGUAUGGGUCGUUCUGCACUCAGCUUAAUCGUGCUCUUACCGGGAUCGCCGUAGAGCAGGAUAAGAACACGCAGGAGGUCUUUGCGCAGGUGAAGCAGAUCUACAAGACUCCGCCUAUCAAGGACUUCGGCGGGUUCAACUUCAGCCAGAUUCUGCCAGACCCAUCUAAGCCGAGCAAGAGGUCCUUUAUUGAGGACCUCUUGUUCAACAAGGUGACUCUGGCAGAUGCUGGCUUUAUCAAGCAGUACGGCGAUUGUCUCGGGGACAUCGCUGCGCGCGAUUUGAUCUGUGCGCAAAAGUUCAACGGGCUCACUGUGCUACCACCUCUCCUGACGGACGAGAUGAUAGCACAGUAUACCAGCGCGCUGUUGGCUGGUACGAUCACUUCUGGUUGGACGUUCGGGGCGGGUGCGGCACUCCAGAUCCCGUUCGCCAUGCAGAUGGCGUACCGGUUCAACGGGAUCGGAGUGACGCAGAACGUCCUGUACGAAAACCAGAAGUUGAUCGCCAACCAGUUCAACAGCGCGAUUGGUAAGAUACAGGACUCCCUGUCGAGUACGGCCUCCGCGUUGGGGAAGCUGCAGGACGUGGUGAACCAGAAUGCUCAGGCGUUGAACACGUUGGUGAAGCAGCUGUCGUCCAACUUCGGGGCGAUAAGUUCGGUGCUGAACGAUAUUCUCAGUCGGCUGGACCCGCCGGAGGCGGAGGUCCAGAUAGAUCGGCUCAUCACUGGUCGCCUCCAGAGUUUGCAGACGUACGUGACUCAGCAGCUCAUCCGGGCUGCUGAGAUACGUGCGUCUGCGAACCUGGCGGCGACCAAGAUGAGCGAGUGCGUGCUGGGGCAGAGCAAGCGGGUGGACUUCUGCGGGAAGGGGUAUCACCUGAUGUCCUUCCCGCAGAGCGCGCCUCACGGGGUGGUCUUCCUGCACGUGACGUAUGUGCCGGCGCAGGAGAAGAACUUCACCACGGCGCCGGCGAUAUGUCACGACGGGAAGGCGCACUUCCCGCGUGAGGGGGUUUUUGUUUCGAACGGGACGCACUGGUUCGUCACGCAGCGCAACUUCUAUGAGCCGCAGAUAAUUACCACUGACAACACGUUUGUCAGUGGUAAUUGUGAUGUGGUCAUAGGGAUCGUGAACAACACGGUCUACGAUCCCCUGCAGCCCGAGCUGGAUAGUUUCAAGGAGGAGCUUGAUAAGUACUUCAAGAAUCAUACUUCCCCGGACGUGGAUCUUGGCGACAUUAGCGGGAUCAACGCUAGUGUCGUCAACAUCCAGAAGGAGAUCGACAGGCUCAAUGAGGUUGCGAAGAACCUCAACGAGAGCCUGAUCGAUCUCCAGGAGUUGGGGAAGUAUGAGCAGUACAUCAAGUGGCCUUGGUACAUCUGGCUCGGGUUCAUCGCGGGGCUGAUCGCGAUCGUGAUGGUCACGAUCAUGUUGUGCUGCAUGACGAGCUGCUGCUCCUGUUUGAAGGGCUGCUGCAGCUGCGGUUCGUGUUGUAAGUUUGACGAGGAUGACUCGGAGCCGGUGCUCAAGGGGGUGAAGCUGCACUACACGUGA
```

Here is a visualization of the secondary structure of the mRNA compared to the secondary structure of a mRNA designed through codon optimization:

<img src="assets/secstructs.png" alt="Secondary structure of standard mRNA and superfolder" width="1000"/>

## What it codes for
```
> S-2P SARS-CoV-2 Spike glycoprotein antigen, prefusion stabilized double proline variant. 1273 amino acids.
MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
```
This exact amino acid sequence is the basis for most mRNA vaccines that are undergoing clinical trials at the time of writing.

```
> S-2P SARS-CoV-2 Spike glycoprotein antigen, prefusion stabilized double proline variant, mutated to strain B.1.351.  1270 amino acids.
MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
```

## Where it comes from

The sequence was designed through the following steps, which have been validated through extensive experiments on model mRNA's by the Das and Barna labs at Stanford University (OpenVaccine consortium, 2021, in prep).

1. A starting sequence predicted to have highly negative (stable) deltaG was produced with the [LinearDesign algorithm](https://arxiv.org/abs/2004.10177) available at [this server](http://rna.baidu.com) (Zhang, 2020).
2. The sequence was further optimized with the [Ribotree-mRNA Monte Carlo Tree Search algorithm](https://www.biorxiv.org/content/10.1101/2020.08.22.262931v1) which is available at the [Eterna software site](http://eternagame.org/about/software).
3. The Ribotree-mRNA runs optimized DegScore, a predictor of overall hydrolysis rate trained on a vast data set of empirical measurements acquired during the [Eterna](https://eternagame.org) [roll-your-own sequence challenges](https://eternagame.org/labs/9830365) (OpenVaccine consortium, 2021, in prep). Training and test data are available at [Kaggle](https://www.kaggle.com/c/stanford-covid-vaccine/).
4. Ribotree-mRNA runs were guided by [EternaFold](https://www.biorxiv.org/content/10.1101/2020.05.29.124511v1), currently the most accurate folding engine for predicting RNA structure properties (Wayment-Steele, 2020a).
5. Ribotree-mRNA runs also favored opening of the first 14 nts to ensure a good binding site for the eukaryotic ribosome (Kozak, 1990; OpenVaccine consortium, in prep).
6. The sequence was screened for robustness of structure and low predicted hydrolysis in the context of numerous combinations of  5' UTR's, 3' UTR's, and poly(A) motifs that are currently in use for COVID-19 mRNA vaccines (see, e.g., Orlandini von Niessen et al., 2008).
7. The sequence was designed based on simulations with standard nucleosides A, C, G, and U. The Stanford OpenVaccine experimental team has evidence that mRNAs stabilized with these standard nucleotides remain stabilized with substitutions such as pseudouridine and its analogs substituting for U (OpenVaccine consortium, 2021, in prep).

Find more details and a comparison to other design methods in [analysis.md](analysis.md). 

## References

Kozak M. Downstream secondary structure facilitates recognition of initiator codons by eukaryotic ribosomes (1990). Proc Natl Acad Sci U S A. 87(21):8301-5. [doi: 10.1073/pnas.87.21.8301](http://dx.doi.org/10.1073/pnas.87.21.8301)

OpenVaccine Consortium (2021). Comparative optimization of messenger RNA structure, stability and expression for RNA therapeutics (in preparation).

Orlandini von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, Diken M, Löwer M, Vallazza B, Beissert T, Bukur V, Kuhn AN, Türeci Ö, Sahin U. (2018), Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. Mol Ther. 27(4):824-836. [doi: 10.1016/j.ymthe.2018.12.011](https://dx.doi.org/10.1016/j.ymthe.2018.12.011)

Wayment-Steele, H.K., Kim, D.S., Choe, C.A., Nicol, J.J., Wellington-Oguri, R., Sperberg, R.A.P., Huang, P., Eterna Participants, Das, R. (2020). Theoretical basis for stabilizing messenger RNA through secondary structure design. bioRxiv, 262931. [doi:10.1101/2020.08.22.262931](https://dx.doi.org/10.1101/2020.08.22.262931)

Wayment-Steele, H.K., Kladwang, W., Eterna Participants, Das, R. (2020). RNA secondary structure packages ranked and improved by high-throughput experiments. bioRxiv, 124511. [10.1101/2020.05.29.124511](https://dx.doi.org/10.1101/2020.05.29.124511)

Zhang, H., Zhang, L., Li, Z., Liu, K., Liu, B., Mathews, D. H., & Huang, L. (2020). LinearDesign: Efficient Algorithms for Optimized mRNA Sequence Design. arXiv preprint [arXiv:2004.10177](https://arxiv.org/abs/2004.10177)

## Questions

For answers to any additional questions that might help accelerate the end of the COVID-19 pandemic, please contact [Rhiju Das](https://daslab.stanford.edu), Stanford University, <a href="mailto:rhiju@stanford.edu">rhiju@stanford.edu</a>.
